Gilead Q2 Earnings Soar As HCV Shines, HIV Rebounds

Big biotech Gilead Sciences (GILD) handily beat analysts' Q2 estimates and raised its guidance Tuesday afternoon, sending its stock up in after-hours trading. Gilead's earnings, excluding one-time items, rose 33.5% over the year-earlier quarter to $3.15 a share, beating analysts' consensus by 44 cents, according to Thomson Reuters. Revenue climbed 26% to $8.24 billion, some $800 million above the Street's number. Gilead duly added another $1

What feeling does this article give you?
Joy
Disgust
Fear
Anger
Sadness

#hashtags to follow:

Gilead Sciences [+]    GILD [+]    Gilead [+]    Thomson Reuters [+]   

More #news: